<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intestinal Entamoeba histolytica amebiasis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intestinal Entamoeba histolytica amebiasis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intestinal Entamoeba histolytica amebiasis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward T Ryan, MD, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intestinal amebiasis is caused by the protozoan <em>Entamoeba histolytica</em>. There are four species of intestinal amebae with identical morphologic characteristics: <em>E. histolytica</em>, <em>E. dispar</em>, <em>E. moshkovskii, and E. bangladeshi</em> [<a href="#rid1">1,2</a>]. Most symptomatic disease is caused by <em>E. histolytica</em>; <em>E. dispar</em> is generally considered nonpathogenic. Reported infections with <em>E. moshkovskii</em> are becoming more frequent, with increasing evidence of its potential pathogenicity emerging [<a href="#rid3">3</a>]. The pathogenic potential of <em>E. bangladeshi </em>remains unclear [<a href="#rid3">3,4</a>].</p><p>Issues related to intestinal <em>E. histolytica</em> infection will be reviewed here; issues related to extraintestinal <em>E. histolytica </em>infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5728.html" rel="external">"Extraintestinal Entamoeba histolytica amebiasis"</a>.)</p><p class="headingAnchor" id="H17143399"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1835806224"><span class="h2">Geographic distribution</span><span class="headingEndMark"> — </span>Amebiasis occurs worldwide; the prevalence is disproportionately increased in resource-limited countries because of poor socioeconomic conditions and sanitation levels. Areas with high rates of amebic infection include India, Africa, Mexico, and parts of Central and South America. The overall prevalence of amebic infection may be as high as 50 percent in some areas [<a href="#rid1">1</a>]. </p><p>In resource-rich countries, amebiasis is generally seen in migrants from and travelers to endemic areas. <em>E. histolytica</em> is not a common cause of travelers' diarrhea, and gastrointestinal infection is uncommon in travelers who have spent less than one month in endemic areas. In one prospective study of German travelers to the tropics, only 0.3 percent had pathogenic <em>E. histolytica</em> infection [<a href="#rid5">5</a>]. Institutionalized patients and in some areas, sexually active men who have sex with men, are also at increased risk of infection [<a href="#rid6">6</a>]. In the United States and Europe, the prevalence of <em>E. histolytica</em> among men who have sex with men (MSM) is relatively low; such individuals are principally colonized with nonpathogenic <em>E. dispar </em>[<a href="#rid1">1,7</a>]. However, in areas where <em>E. histolytica</em> is much more prevalent, it does occur among MSM, and invasive, extraintestinal amebiasis (eg, hepatic abscesses) is more frequent in immunosuppressed patients with HIV [<a href="#rid1">1,8-10</a>].</p><p class="headingAnchor" id="H17143536"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>The parasite exists in two forms, a cyst stage (the infective form) and a trophozoite stage (the form that causes invasive disease)  (<a class="graphic graphic_figure graphicRef69977" href="/z/d/graphic/69977.html" rel="external">figure 1</a>). Infection occurs following ingestion of amebic cysts; this is usually via contaminated food or water but can be associated with sexual transmission through fecal-oral contact, so infection can occur in nonendemic areas among individuals who have never traveled abroad [<a href="#rid6">6,11</a>]. Cysts can remain viable in the environment for weeks to months, and ingestion of a single cyst is sufficient to cause disease. </p><p class="headingAnchor" id="H384770370"><span class="h2">Risk factors for severe disease</span><span class="headingEndMark"> — </span>Worldwide, approximately 50 million people develop colitis or extraintestinal disease, with over 100,000 deaths annually [<a href="#rid12">12</a>]. Factors that influence whether infection leads to asymptomatic or invasive disease include the <em>E. histolytica</em> strain and host factors such as genetic susceptibility, age, and immune status [<a href="#rid1">1,13</a>]. Risk factors for severe disease and increased mortality include young age, pregnancy, corticosteroid treatment, malignancy, malnutrition, and alcoholism [<a href="#rid14">14-16</a>]. A systematic review of patients with amoebic colitis who received steroids for initially misdiagnosed colitis noted that rapid progression of disease following steroid therapy was common, and 25 percent of patients died [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Infection with <em>E. dispar</em> occurs approximately 10 times more frequently than infection with <em>E. histolytica, </em>although symptoms are more likely to result from <em>E. histolytica</em> [<a href="#rid1">1</a>]. The host-parasite interaction is complex, and the virulence of different strains of <em>E. histolytica</em> is variable [<a href="#rid18">18,19</a>]. After ingestion of a cyst, the cyst passes through the stomach to the small intestine, where it excysts to form a trophozoite. The trophozoites can invade and penetrate the mucous barrier of the colon, causing tissue destruction and increased intestinal secretion and can thereby ultimately lead to bloody diarrhea [<a href="#rid20">20</a>]. The trophozoite is able to kill both epithelial cells and inflammatory cells, which is thought to occur through a number of different mechanisms, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Secretion of proteinases by the trophozoites</p><p class="bulletIndent1"><span class="glyph">●</span>Lysis of target cells via a contact-dependent mechanism</p><p class="bulletIndent1"><span class="glyph">●</span>Killing of mammalian cells by apoptosis (programmed cell death)</p><p class="bulletIndent1"><span class="glyph">●</span>Formation of amebapores, a family of small peptides that can form pores in lipid bilayers, resulting in cytolysis of infected cells</p><p class="bulletIndent1"><span class="glyph">●</span>Changes in intestinal permeability, probably via disruption of tight-junction proteins</p><p></p><p>The pathogenicity of amebic trophozoites is facilitated by adherence to colonic epithelial cells via a specific lectin (the galactose-N-acetylgalactosamine lectin) [<a href="#rid14">14</a>]. Mammalian cells without N-terminal galactose or N-acetylgalactosamine residues are resistant to adherence by amebic trophozoites, which is consistent with an important role for the lectin in adhesion. This lectin also plays a role in immunity, since mucosal immunity against the lectin seems to mediate some degree of protection from invasive disease following colonization. One study from Bangladesh showed that children with a mucosal IgA response against the lectin had 86 percent fewer new infections during a one-year period than children without this response [<a href="#rid21">21</a>] and, when reinfected, had a lower incidence of symptomatic disease over a four-year follow-up period [<a href="#rid22">22</a>]. Other amebic molecules such as lipophosphopeptidoglycan, peroxiredoxin, arginase, and lysine, and glutamic acid-rich proteins are also implicated in the pathogenesis of amoebiasis [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Clinical manifestations can vary from asymptomatic infection to acute fulminant colitis in rare circumstances. Most infection is asymptomatic; clinical manifestations include amebic dysentery and extraintestinal disease [<a href="#rid20">20,24</a>]. Extraintestinal manifestations include amebic liver abscess and other rarer manifestations such as pulmonary, cardiac, or brain involvement; these are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic infection</strong> – The majority of entamoeba infections are asymptomatic; this includes 90 percent of <em>E. histolytica</em> infections. <em>E. dispar</em> is generally considered to be nonpathogenic, although there have been reports describing <em>E. dispar</em> as a potential cause of amebic liver abscess [<a href="#rid25">25,26</a>] and chronic diarrhea [<a href="#rid27">27</a>]. While <em>E. moshkovskii</em> was traditionally thought to be nonpathogenic, it has also been associated with diarrhea [<a href="#rid28">28,29</a>]. The pathogenicity of <em>E. bangladeshi</em> remains to be investigated [<a href="#rid30">30</a>]. </p><p></p><p>Amebic colitis has been recognized in asymptomatic patients. Among 5193 asymptomatic individuals in Japan undergoing colonoscopy for evaluation of positive fecal occult blood tests, for example, four were found to have amebic ulcerative lesions in the cecum or ascending colon [<a href="#rid31">31</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical acute and subacute disease</strong> – Clinical amebiasis generally has a subacute onset, usually over one to three weeks. Symptoms range from mild diarrhea to severe dysentery, producing abdominal pain (12 to 80 percent), diarrhea (94 to 100 percent), and bloody stools (94 to 100 percent), to fulminant amebic colitis. Chronic non-dysenteric colitis is the most frequent form of amebiasis in people of all ages [<a href="#rid32">32</a>]. Rarely, acute fulminant necrotizing amebic colitis presents with life-threatening lower gastrointestinal bleeding without diarrhea [<a href="#rid33">33</a>]. Weight loss occurs in about half of patients, and fever occurs in up to 38 percent. </p><p></p><p>Amebic dysentery consists of diarrhea with visible blood and mucus in stools and the presence of hematophagous trophozoites (trophozoites with ingested red blood cells) in stools or tissues [<a href="#rid34">34</a>]. Stool specimens are frequently positive for blood in the setting of invasive intestinal amebic disease. The presence of ingested erythrocytes is not pathognomonic for <em>E. histolytica</em> infection  (<a class="graphic graphic_picture graphicRef57615" href="/z/d/graphic/57615.html" rel="external">picture 1</a>); ingested erythrocytes may also be observed with <em>E. dispar</em>. Fecal leukocytes are not always present since white cells may be destroyed by the organisms. In one study of travelers and migrants, clinical features of <em>E. histolytica</em> infection included blood in stool (sensitivity and specificity 30 and 100 percent, respectively), mucus in stool (sensitivity and specificity 22 and 100 percent, respectively), and abdominal cramps (sensitivity and specificity 44 and 90 percent, respectively) [<a href="#rid35">35</a>]. Neither watery diarrhea nor fever were significantly associated with diagnosis of <em>E. histolytica</em>. </p><p>Fulminant colitis with bowel necrosis leading to perforation, and peritonitis has been observed in approximately 0.5 percent of cases; associated mortality rate is more than 40 percent [<a href="#rid36">36-38</a>]. Toxic megacolon can also develop.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic diarrhea</strong> – Rarely, intestinal amebiasis may present as a chronic syndrome of diarrhea, weight loss, and abdominal pain without dysentery, lasting for years and mimicking inflammatory bowel disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other intestinal manifestations</strong> – Uncommonly, localized colonic infection resulting in a mass of granulation tissue forming an ameboma can occur, mimicking colon cancer [<a href="#rid39">39,40</a>]. Patients with amebomas usually are found to have a tender palpable mass. Other rare complications of amebiasis include appendicitis, perianal cutaneous amebiasis, and rectovaginal fistulae [<a href="#rid41">41,42</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1899005995"><span class="h2">When to suspect intestinal amebiasis</span><span class="headingEndMark"> — </span>Intestinal amebiasis is generally suspected in the setting of acute to subacute diarrhea (especially if the diarrhea is bloody) and relevant epidemiologic exposure (residence in or travel to an area where <em>E. histolytica</em> is prevalent). Intestinal amebiasis should also be suspected in patients with persistent diarrhea in whom the initial workup was negative, especially in those with risk factors (eg, institutionalized individuals, sexually active MSM). </p><p class="headingAnchor" id="H1851442873"><span class="h2">Diagnostic evaluation</span><span class="headingEndMark"> — </span>The diagnosis of intestinal amebiasis can be made by stool microscopy, stool antigen testing, or stool PCR [<a href="#rid43">43</a>]. The test of choice is usually determined by availability. When available, we prefer stool PCR because of its high sensitivity and specificity and its ability to distinguish <em>E. histolytica</em> from <em>E. dispar</em> and <em>E. moshkovskii</em>. If PCR is not available, stool antigen is the next best choice as it is also able to distinguish between various <em>Entamoeba</em> strains. Stool microscopy is labor intensive and has limited sensitivity; however this may be the only tool available in some settings. If stool microscopy is used, we prefer to send at minimum three different specimens on different days to optimize detection of organisms. This approach detects 85 to 95 percent of infections. Stool microscopy is not able to differentiate between <em>Entamoeba</em> strains, requires specialized expertise, and is subject to operator error [<a href="#rid44">44</a>].</p><p>Serology is not very helpful in diagnosing an <em>E. histolytica</em> infection, especially in endemic areas, as antibodies can persist for years after infection. </p><p class="headingAnchor" id="H3551945246"><span class="h2">Approach to incidental cysts found on screening</span><span class="headingEndMark"> — </span>Occasionally, amebic cysts may be detected incidentally on Papanicolaou smears, stool microscopy, or during a sigmoidoscopy or colonoscopy. If entamoebic cysts are detected, we proceed with sending either a stool antigen or PCR to distinguish <em>E. histolytica</em> infection from that of <em>E. dispar</em> or <em>E. moshkovskii</em>. If neither stool antigen nor PCR is available, we evaluate for any clinical signs of infection. Treatment is reasonable in those with symptoms consistent with <em>E. histolytica</em> infection. (See <a class="local">'Treatment'</a> below.)</p><p>If <em>Entamoeba</em> cysts are detected on a cervical pap smear, this is likely to be <em>Entamoeba gingivalis</em>, rather than <em>Entamoeba histolytica</em>. <em>Entamoeba gingivalis</em> is non-pathogenic; no further evaluation or treatment is warranted. </p><p class="headingAnchor" id="H982979812"><span class="h2">Diagnostic tests</span><span class="headingEndMark"> — </span>Tools for diagnosis of intestinal amebiasis include stool microscopy, stool and serum antigen detection, stool polymerase chain reaction (PCR), serology, and colonoscopy with histologic examination. Serologic testing cannot distinguish between acute, currently active infection and previous infection. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stool</strong> <strong>microscopy</strong> – The demonstration of cysts or trophozoites in the stool suggests intestinal amebiasis, but microscopy cannot differentiate between <em>E. histolytica</em> and <em>E. dispar</em> or <em>E. moshkovskii</em> strains. In addition, microscopy requires specialized expertise and is subject to operator error [<a href="#rid44">44</a>].</p><p></p><p>Organism excretion can vary; a minimum of three specimens on separate days should be sent to detect 85 to 95 percent of infections. Specimens can be concentrated and stained with iodine to detect cysts. To look for trophozoites, a <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> wet mount and a fresh smear stained with iron hematoxylin and/or Wheatley's trichrome should be performed; fixation with polyvinyl alcohol for delayed staining is often useful.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antigen testing</strong> – Antigen detection is sensitive, specific, rapid, easy to perform, and can distinguish between <em>E. histolytica</em> and <em>E. dispar</em>. Stool and serum antigen detection assays that use monoclonal antibodies to bind to epitopes present on pathogenic <em>E. histolytica</em> strains (but not on nonpathogenic <em>E. dispar</em> strains) are commercially available for diagnosis of <em>E. histolytica</em> infection [<a href="#rid45">45</a>]. Antigen detection kits using enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, or immunofluorescence have been developed [<a href="#rid43">43,46</a>]. Antigen detection has many advantages, including ease and rapidity of the tests, capacity to differentiate between strains, greater sensitivity than microscopy, and potential for diagnosis in early infection and in endemic areas (where serology is less useful).</p><p></p><p>A number of commercial assays with variable reported sensitivities and specificities have been developed [<a href="#rid43">43</a>]. The TechLab <em>E. histolytica</em> stool antigen test is an ELISA test that is specific for <em>E. histolytica</em>. The assay detects the <em>E. histolytica</em>-derived Gal/GalNAc lectin in stool specimen; it has a sensitivity of 87 percent and a specificity of &gt;90 percent compared with culture [<a href="#rid47">47,48</a>]. A study comparing the TechLab <em>E. histolytica</em>-specific antigen detection test with PCR assays showed comparable sensitivities when performed directly on fresh stool specimens [<a href="#rid48">48</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular methods</strong> – Detection of parasitic DNA or RNA in stool via probes can also be used to diagnose amebic infection and to differentiate between the three different strains.</p><p></p><p>A number of commercial PCR tests that can detect <em>E. histolytica</em> in stool specimens are available [<a href="#rid49">49-51</a>]. These include conventional PCR, nested PCR, real-time PCR, multiplex PCR, and loop-mediated isothermal amplification assay [<a href="#rid43">43</a>]. Most of the commercial PCR assays have close to 100 percent sensitivity and specificity [<a href="#rid43">43,52,53</a>], and PCR is about 100 times more sensitive than stool antigen tests [<a href="#rid54">54</a>]. In addition, PCR can differentiate between pathogenic and nonpathogenic amebae [<a href="#rid55">55-57</a>], and many of the PCR tests allow the simultaneous detection of multiple pathogens.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serology</strong> – <em>E. histolytica</em> infection results in the development of antibodies; <em>E. dispar</em> infection does not. Antibodies are detectable within five to seven days of acute infection and may persist for years. Approximately 10 to 35 percent of uninfected individuals in endemic areas have antiamebic antibodies due to previous infection with <em>E. histolytica</em> [<a href="#rid1">1</a>]. Therefore, negative serology is helpful for exclusion of disease, but positive serology cannot distinguish between acute and previous infection, especially in endemic settings.</p><p></p><p>Indirect hemagglutination (IHA) is the most sensitive serologic assay; it is positive in approximately 90 percent of patients with symptomatic intestinal infection [<a href="#rid1">1</a>]. Agar gel diffusion and counterimmunopheresis are less sensitive than IHA but usually only remain positive for 6 to 12 months, which may make them more useful in endemic areas. A commercially available ELISA that has a sensitivity of 93 percent compared with IHA has also been developed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visual inspection of the colon</strong> – Sigmoidoscopy and/or colonoscopy can be performed to make the diagnosis of amebiasis and to exclude other causes of symptoms. However, colonoscopy is not appropriate as a routine diagnostic test since presence of amebic ulcerations increase the likelihood of perforation during instillation of air to expand the colon.</p><p></p><p>Cecum and colon are the most common sites of involvement [<a href="#rid58">58</a>]. In one study, endoscopic findings of amebic colitis (including discrete ulcers or erosions) were observed in the cecum, rectum, ascending colon, transverse colon, sigmoid colon, and descending colon (93, 45, 28, 25, 20, and 15 percent, respectively) [<a href="#rid59">59</a>]. Typical findings include diffuse wall thickening, skip lesions, or pancolitis [<a href="#rid60">60</a>].</p><p>Scrapings or biopsy specimens, best taken from the edge of ulcers, may be positive for cysts or trophozoites on microscopy, and antigen testing for <em>E. histolytica</em> may be positive. Colonic lesions in amebic dysentery range from nonspecific mucosal thickening and inflammation to classic flask-shaped amebic ulcers  (<a class="graphic graphic_picture graphicRef66341" href="/z/d/graphic/66341.html" rel="external">picture 2</a> and <a class="graphic graphic_diagnosticimage graphicRef96413" href="/z/d/graphic/96413.html" rel="external">image 1</a>).</p><p class="headingAnchor" id="H9471115"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of <em>E. histolytica</em> amebiasis includes other causes of acute diarrhea or bloody stools, particularly bacterial pathogens including <em>Shigella, Escherichia coli, Salmonella, Campylobacter, Clostridioides difficile,</em> and some <em>Vibrio</em> species. These are distinguished based on culture results or molecular diagnostic assays. Intestinal tuberculosis should also be considered. Noninfectious etiologies include ischemic bowel and inflammatory bowel disease.</p><p class="headingAnchor" id="H13"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3130500016"><span class="h2">Entamoeba histolytica</span><span class="headingEndMark"> — </span>The goals of antimicrobial therapy of intestinal amebiasis are to eliminate the invading trophozoites and to eradicate intestinal carriage of the organism.</p><p class="headingAnchor" id="H3787604610"><span class="h3">Asymptomatic infection</span><span class="headingEndMark"> — </span><em>E. histolytica</em> may be found incidentally in the course of screening or evaluation of other conditions. All <em>E. histolytica</em> infections should be treated even in the absence of symptoms, given the potential risk of developing invasive disease and the risk of spread to family members [<a href="#rid1">1,20</a>]. Patients without any symptoms or signs of active disease should be treated with an intraluminal agent (eg, <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> or diloxanide furoate). </p><p>Intraluminal agents include <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> (25 to 30 mg/kg per day orally in three divided doses for 7 days) or diloxanide furoate (500 mg orally three times daily for adults and 20 mg/kg per day in three divided doses for children for 10 days). Choice of agent largely depends on local drug availability. Availability of these medications, particularly diloxanide furoate, is limited. Paromomycin is safe in pregnancy. (See <a class="local">'Special considerations in pregnant patients'</a> below.) </p><p><a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">Nitazoxanide</a> has been proposed as an alternative luminal amoebicide agent [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H3196487571"><span class="h3">Symptomatic infection</span><span class="headingEndMark"> — </span>Patients with symptomatic infections require systemic therapy, followed by an intraluminal agent. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>All symptomatic patients </strong>–<strong> </strong>Intraluminal elimination is similar to those with asymptomatic infections and is discussed above. (See <a class="local">'Asymptomatic infection'</a> above.)</p><p></p><p class="bulletIndent1">Approach to systemic therapy in patients with symptomatic disease is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate disease</strong> – Patients exhibiting mild to moderate disease (eg, diarrhea, abdominal pain) require systemic treatment with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (alternative therapies include <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>, ornidazole, <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">secnidazole</a>, and <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>). A 10-day course of metronidazole eliminates intraluminal infection in many cases, but subsequent treatment with an intraluminal agent is still warranted [<a href="#rid61">61</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fulminant colitis/peritonitis/toxic megacolon</strong> – Severe presentations and complications of severe disease require empiric broad-spectrum antibiotics for possible superimposed bacterial infection (ie, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> plus treatment for gram-negative enteric organisms). Occasionally, surgical intervention, such as a colectomy, is required in the setting of toxic megacolon. Management of intra-abdominal infections is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/101694.html" rel="external">"Antimicrobial approach to intra-abdominal infections in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15075.html" rel="external">"Overview of gastrointestinal tract perforation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extraluminal disease</strong> – Patients with infection outside of the colon, such as amebic liver abscess, require <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, along with site-specific management. (See  <a class="medical medical_review" href="/z/d/html/5728.html" rel="external">"Extraintestinal Entamoeba histolytica amebiasis"</a>.)</p><p></p><p>Dosing for <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is 500 to 750 mg by mouth three times daily in adults and 35 to 50 mg/kg per day in three divided doses in children for 7 to 10 days. Shorter duration of metronidazole is generally not recommended [<a href="#rid62">62,63</a>]. Metronidazole is well absorbed from the gastrointestinal tract; intravenous therapy offers no significant advantage as long as the patient can take oral medications and has no major defect in small bowel absorption.</p><p>Alternatives to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> include other nitroimidazoles, such as <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> (2 g by mouth daily for 3 days), ornidazole (500 mg by mouth daily in adults and 40 mg/kg daily dose in children for 3 days), and <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">secnidazole</a> (2 g/day in adults and 30 mg/kg/day in children for 1 to 3 days). Efficacy and comparative data are limited, thus, choice of agent largely depends on drug availability and cost [<a href="#rid34">34,62,63</a>]. Tinidazole cure rates of 90 to 93 percent have been observed [<a href="#rid62">62-64</a>]. In a systematic review, treatment with tinidazole was associated with a 72 percent reduction in clinical failures compared with metronidazole [<a href="#rid34">34</a>]. Tinidazole is also better tolerated than metronidazole. However, cost and lack of availability prohibit its use in many settings. </p><p class="headingAnchor" id="H2713681152"><span class="h3">Special considerations in pregnant patients</span><span class="headingEndMark"> — </span>Severe amebic colitis due to <em>E. histolytica</em> can cause significant morbidity and potential mortality during pregnancy. It is important to confirm <em>E. histolytica</em> as the causative pathogen. (See <a class="local">'Diagnosis'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>For pregnant women with mild to moderate amebic colitis due to <em>E. histolytica </em>without evidence of extraluminal disease, we favor treatment with <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> to avoid the teratogenic toxicity of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid65">65</a>]. Paromomycin is an oral aminoglycoside with poor intestinal absorption. Diloxanide is not recommended in pregnancy. If there is no clinical improvement, further treatment with metronidazole could be considered after determining the risks and benefits to mother and fetus.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For pregnant women with severe amebic colitis due to <em>E. histolytica</em>, we suggest <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> rather than <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a>. Paromomycin should be avoided in the setting of severe amebic colitis, given that in this setting, there may be breakdown of the intestinal barrier with risk for systemic absorption. Paromomycin alone is also unlikely to be effective in setting of severe disease [<a href="#rid66">66</a>]. However, we acknowledge that use of metronidazole in pregnancy is controversial; it crosses the placenta and rapidly enters the fetal circulation. There are no well-controlled studies demonstrating safety of metronidazole in pregnancy. Therefore, it should be used only in the setting of severe illness (eg, if the risks to the mother associated with deferring treatment outweigh potential harm to the fetus).</p><p></p><p class="headingAnchor" id="H3149546202"><span class="h2">Entamoeba moshkovskii</span><span class="headingEndMark"> — </span>The need for treatment of <em>E. moshkovskii </em>is uncertain; although data are very limited, we suggest treatment for symptomatic infection, using the same approach as for symptomatic <em>E. histolytica</em>. (See <a class="local">'Symptomatic infection'</a> above.)</p><p class="headingAnchor" id="H3049863684"><span class="h2">Entamoeba dispar</span><span class="headingEndMark"> — </span><em>E. dispar</em> infections are thought to be nonpathogenic and therefore do not require treatment. In countries where amebic infections are endemic, asymptomatic patients incidentally found to have stools positive for amebae are frequently presumed to have infection with <em>E. dispar</em> and are not further evaluated or treated. As antigen tests that can differentiate between <em>E. dispar</em> and <em>E. histolytica</em> become more widely available in these countries, this practice may change. </p><p class="headingAnchor" id="H19"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention of amebic infection in travelers to endemic areas involves avoidance of untreated water in endemic areas and uncooked food, such as fruit and vegetables that may have been washed in untreated water. Amebic cysts are resistant to chlorine at the levels used in water supplies, but disinfection with iodine may be effective. Avoiding sexual practices that may lead to fecal-oral contact is also advisable. (See  <a class="medical medical_review" href="/z/d/html/3898.html" rel="external">"Travel advice", section on 'Behavioral precautions'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Vaccine development</span><span class="headingEndMark"> — </span>There is some evidence of partial acquired immunity to the organism. Protection from invasive disease has been associated with mucosal IgA antibodies to the amebic adherence lectin [<a href="#rid21">21,22</a>], and Gal-lectin based vaccinations have conferred some protection in various animal models against <em>E. histolytica</em> infections [<a href="#rid67">67</a>]. However, recurrent intestinal infection and persistent colonization may occur despite detectable antiamebic antibodies [<a href="#rid68">68</a>]. Thus, it seems probable that acquired, but incomplete, immunity against infection occurs, and a vaccine that can reduce infection and/or invasive disease may therefore be feasible.</p><p>The relative importance of systemic and mucosal, cellular, and humoral immunity is unclear. Several amebic proteins associated with virulence have been identified and are being studied as potential vaccine components. Development of both parenteral and oral vaccines for humans is in progress [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H7061138"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intestinal amebiasis is caused by the protozoan <em>Entamoeba histolytica</em>. There are four species of intestinal amebae with identical morphologic characteristics: E. histolytica, E. dispar, E. moshkovskii, and E. bangladeshi. <em>E. dispar</em> is nonpathogenic and does not cause clinical disease; most symptomatic disease is caused by <em>E. histolytica</em>. The pathogenic potential of <em>E. moshkovskii</em> remains unclear. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Amebiasis occurs worldwide; the prevalence is disproportionately increased in resource-limited countries because of poor socioeconomic conditions and sanitation levels. Areas with high rates of amebic infection include India, Africa, Mexico, and parts of Central and South America. In resource-rich countries, amebiasis is generally seen in migrants from and travelers to endemic areas. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Clinical amebiasis generally has a subacute onset, usually over one to three weeks. Symptoms range from mild diarrhea to severe dysentery, producing abdominal pain, diarrhea, and bloody stools. Fulminant colitis with bowel necrosis leading to perforation and peritonitis can occur, as can toxic megacolon. Amebic colitis has been recognized in asymptomatic patients as well. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>When to suspect intestinal amebiasis </strong>– Intestinal amebiasis is generally suspected in the setting of acute to subacute diarrhea (especially if the diarrhea is bloody) and relevant epidemiologic exposure (residence in or travel to an area where <em>E. histolytica </em>is prevalent). Intestinal amebiasis should also be suspected in patients with persistent diarrhea in whom the initial workup was negative, especially in those with risk factors (eg, institutionalized individuals, sexually active MSM). (See <a class="local">'When to suspect intestinal amebiasis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Approach to diagnosis </strong>– Diagnosis is generally made by microscopy, antigen testing, or PCR methods. Advantages of antigen testing and PCR are that they are sensitive and can distinguish between <em>E. histolytica </em>and <em>E. dispar </em>infections. When available, we prefer stool PCR because of its high sensitivity and specificity and its ability to distinguish <em>E. histolytica </em>from <em>E. dispar </em>and <em>E. moshkovskii.</em> (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– All<em> E. histolytica</em> infections should be treated, even in the absence of symptoms, given the potential risk of developing invasive disease and the risk of spread to family members. The goals of antibiotic therapy of intestinal amebiasis are to eliminate the invading trophozoites and to eradicate intestinal carriage of the organism. (See <a class="local">'Entamoeba histolytica'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For all infections, regardless of the presence of symptoms, we suggest treatment with <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> to eliminate intraluminal cysts (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Dosing is outlined above. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For symptomatic infections, we suggest either <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> or <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> rather than an intraluminal agent alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment with an intraluminal agent follows systemic treatment. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In cases of severe or fulminant infection (eg, fulminant colitis/peritonitis/toxic megacolon), empiric broad spectrum antibiotics to treat gram-negative enteric organisms is also appropriate. (See  <a class="medical medical_review" href="/z/d/html/101694.html" rel="external">"Antimicrobial approach to intra-abdominal infections in adults", section on 'High-risk community-acquired infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– Prevention of amebic infection in travelers to endemic areas involves avoidance of untreated water in endemic areas and uncooked food, such as fruit and vegetables, which may have been washed in untreated water. Amebic cysts are resistant to chlorine at the levels used in water supplies, but disinfection with iodine may be effective. (See <a class="local">'Prevention'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Peterson KM, Singh U, Petri WA Jr. Enteric Amebiasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant R, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.614.</li><li><a class="nounderline abstract_t">Parija SC, Mandal J, Ponnambath DK. Laboratory methods of identification of Entamoeba histolytica and its differentiation from look-alike Entamoeba spp. Trop Parasitol 2014; 4:90.</a></li><li><a class="nounderline abstract_t">Heredia RD, Fonseca JA, López MC. Entamoeba moshkovskii perspectives of a new agent to be considered in the diagnosis of amebiasis. Acta Trop 2012; 123:139.</a></li><li><a class="nounderline abstract_t">Royer TL, Gilchrist C, Kabir M, et al. Entamoeba bangladeshi nov. sp., Bangladesh. Emerg Infect Dis 2012; 18:1543.</a></li><li><a class="nounderline abstract_t">Weinke T, Friedrich-Jänicke B, Hopp P, Janitschke K. Prevalence and clinical importance of Entamoeba histolytica in two high-risk groups: travelers returning from the tropics and male homosexuals. J Infect Dis 1990; 161:1029.</a></li><li><a class="nounderline abstract_t">Salit IE, Khairnar K, Gough K, Pillai DR. A possible cluster of sexually transmitted Entamoeba histolytica: genetic analysis of a highly virulent strain. Clin Infect Dis 2009; 49:346.</a></li><li><a class="nounderline abstract_t">Morán P, Ramos F, Ramiro M, et al. Infection by human immunodeficiency virus-1 is not a risk factor for amebiasis. Am J Trop Med Hyg 2005; 73:296.</a></li><li><a class="nounderline abstract_t">Hung CC, Deng HY, Hsiao WH, et al. Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan. Arch Intern Med 2005; 165:409.</a></li><li><a class="nounderline abstract_t">Hung CC, Ji DD, Sun HY, et al. Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Negl Trop Dis 2008; 2:e175.</a></li><li><a class="nounderline abstract_t">Watanabe K, Aoki T, Nagata N, et al. Clinical significance of high anti-entamoeba histolytica antibody titer in asymptomatic HIV-1-infected individuals. J Infect Dis 2014; 209:1801.</a></li><li><a class="nounderline abstract_t">Billet AC, Salmon Rousseau A, Piroth L, Martins C. An underestimated sexually transmitted infection: amoebiasis. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Bercu TE, Petri WA, Behm JW. Amebic colitis: new insights into pathogenesis and treatment. Curr Gastroenterol Rep 2007; 9:429.</a></li><li><a class="nounderline abstract_t">Ximénez C, Morán P, Rojas L, et al. Reassessment of the epidemiology of amebiasis: state of the art. Infect Genet Evol 2009; 9:1023.</a></li><li><a class="nounderline abstract_t">Stanley SL Jr. Amoebiasis. Lancet 2003; 361:1025.</a></li><li><a class="nounderline abstract_t">Kantor M, Abrantes A, Estevez A, et al. Entamoeba Histolytica: Updates in Clinical Manifestation, Pathogenesis, and Vaccine Development. Can J Gastroenterol Hepatol 2018; 2018:4601420.</a></li><li><a class="nounderline abstract_t">Shijubou N, Sumi T, Kamada K, et al. Fulminant amebic colitis in a patient with concomitant cytomegalovirus infection after systemic steroid therapy: A case report. World J Clin Cases 2021; 9:3726.</a></li><li><a class="nounderline abstract_t">Shirley DA, Moonah S. Fulminant Amebic Colitis after Corticosteroid Therapy: A Systematic Review. PLoS Negl Trop Dis 2016; 10:e0004879.</a></li><li><a class="nounderline abstract_t">Padilla-Vaca F, Anaya-Velázquez F. Insights into Entamoeba histolytica virulence modulation. Infect Disord Drug Targets 2010; 10:242.</a></li><li><a class="nounderline abstract_t">Mortimer L, Chadee K. The immunopathogenesis of Entamoeba histolytica. Exp Parasitol 2010; 126:366.</a></li><li><a class="nounderline abstract_t">Haque R, Huston CD, Hughes M, et al. Amebiasis. N Engl J Med 2003; 348:1565.</a></li><li><a class="nounderline abstract_t">Haque R, Duggal P, Ali IM, et al. Innate and acquired resistance to amebiasis in bangladeshi children. J Infect Dis 2002; 186:547.</a></li><li><a class="nounderline abstract_t">Haque R, Mondal D, Duggal P, et al. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun 2006; 74:904.</a></li><li><a class="nounderline abstract_t">Lejeune M, Rybicka JM, Chadee K. Recent discoveries in the pathogenesis and immune response toward Entamoeba histolytica. Future Microbiol 2009; 4:105.</a></li><li><a class="nounderline abstract_t">Shirley DT, Farr L, Watanabe K, Moonah S. A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis. Open Forum Infect Dis 2018; 5:ofy161.</a></li><li><a class="nounderline abstract_t">Ximénez C, Cerritos R, Rojas L, et al. Human amebiasis: breaking the paradigm? Int J Environ Res Public Health 2010; 7:1105.</a></li><li><a class="nounderline abstract_t">da Silva CAV, de Oliveira IMC, Cruz RE, et al. South American Entamoeba dispar strains produce amoebic liver abscesses with different pathogenicities and evolutionary kinetics. Acta Trop 2021; 224:106114.</a></li><li><a class="nounderline abstract_t">Graffeo R, Archibusacci CM, Soldini S, et al. Entamoeba dispar: A Rare Case of Enteritis in a Patient Living in a Nonendemic Area. Case Rep Gastrointest Med 2014; 2014:498058.</a></li><li><a class="nounderline abstract_t">Yakoob J, Abbas Z, Beg MA, et al. Entamoeba species associated with chronic diarrhoea in Pakistan. Epidemiol Infect 2012; 140:323.</a></li><li><a class="nounderline abstract_t">Shimokawa C, Kabir M, Taniuchi M, et al. Entamoeba moshkovskii is associated with diarrhea in infants and causes diarrhea and colitis in mice. J Infect Dis 2012; 206:744.</a></li><li><a class="nounderline abstract_t">Ali IK. Intestinal amebae. Clin Lab Med 2015; 35:393.</a></li><li><a class="nounderline abstract_t">Okamoto M, Kawabe T, Ohata K, et al. Amebic colitis in asymptomatic subjects with positive fecal occult blood test results: clinical features different from symptomatic cases. Am J Trop Med Hyg 2005; 73:934.</a></li><li><a class="nounderline abstract_t">Morán P, Serrano-Vázquez A, Rojas-Velázquez L, et al. Amoebiasis: Advances in Diagnosis, Treatment, Immunology Features and the Interaction with the Intestinal Ecosystem. Int J Mol Sci 2023; 24.</a></li><li><a class="nounderline abstract_t">Chandnani S, Udgirkar S, Jain SS, et al. Massive Lower Gastrointestinal Bleeding Due to Fulminant Necrotizing Amebic Colitis: A Diagnostic and Therapeutic Challenge. J Assoc Physicians India 2019; 67:79.</a></li><li><a class="nounderline abstract_t">Gonzales MLM, Dans LF, Sio-Aguilar J. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev 2019; 1:CD006085.</a></li><li><a class="nounderline abstract_t">Van Den Broucke S, Verschueren J, Van Esbroeck M, et al. Clinical and microscopic predictors of Entamoeba histolytica intestinal infection in travelers and migrants diagnosed with Entamoeba histolytica/dispar infection. PLoS Negl Trop Dis 2018; 12:e0006892.</a></li><li><a class="nounderline abstract_t">Athié-Gutiérrez C, Rodea-Rosas H, Guízar-Bermúdez C, et al. Evolution of surgical treatment of amebiasis-associated colon perforation. J Gastrointest Surg 2010; 14:82.</a></li><li><a class="nounderline abstract_t">Ortiz-Castillo F, Salinas-Aragón LE, Sánchez-Aguilar M, et al. Amoebic toxic colitis: analysis of factors related to mortality. Pathog Glob Health 2012; 106:245.</a></li><li><a class="nounderline abstract_t">Jain BK, Garg PK, Kumar A, et al. Colonic perforation with peritonitis in amoebiasis: a tropical disease with high mortality. Trop Gastroenterol 2013; 34:83.</a></li><li><a class="nounderline abstract_t">Stockinger ZT. Colonic ameboma: its appearance on CT: report of a case. Dis Colon Rectum 2004; 47:527.</a></li><li><a class="nounderline abstract_t">Misra SP, Misra V, Dwivedi M. Ileocecal masses in patients with amebic liver abscess: etiology and management. World J Gastroenterol 2006; 12:1933.</a></li><li><a class="nounderline abstract_t">Kenner BM, Rosen T. Cutaneous amebiasis in a child and review of the literature. Pediatr Dermatol 2006; 23:231.</a></li><li><a class="nounderline abstract_t">Goyal A, Goyal S, Gupta CR. Acute amoebic appendicitis: An unusual presentation of a usual infection. Indian J Pathol Microbiol 2019; 62:169.</a></li><li><a class="nounderline abstract_t">Saidin S, Othman N, Noordin R. Update on laboratory diagnosis of amoebiasis. Eur J Clin Microbiol Infect Dis 2019; 38:15.</a></li><li><a class="nounderline abstract_t">Rayan HZ. Microscopic overdiagnosis of intestinal amoebiasis. J Egypt Soc Parasitol 2005; 35:941.</a></li><li><a class="nounderline abstract_t">González-Ruíz A, Haque R, Rehman T, et al. Further diagnostic use of an invasive-specific monoclonal antibody against Entamoeba histolytica. Arch Med Res 1992; 23:281.</a></li><li><a class="nounderline abstract_t">Spadafora LJ, Kearney MR, Siddique A, et al. Species-Specific Immunodetection of an Entamoeba histolytica Cyst Wall Protein. PLoS Negl Trop Dis 2016; 10:e0004697.</a></li><li><a class="nounderline abstract_t">Haque R, Kress K, Wood S, et al. Diagnosis of pathogenic Entamoeba histolytica infection using a stool ELISA based on monoclonal antibodies to the galactose-specific adhesin. J Infect Dis 1993; 167:247.</a></li><li><a class="nounderline abstract_t">Haque R, Petri WA Jr. Diagnosis of amebiasis in Bangladesh. Arch Med Res 2006; 37:273.</a></li><li><a class="nounderline abstract_t">Haque R, Ali IK, Akther S, Petri WA Jr. Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of Entamoeba histolytica infection. J Clin Microbiol 1998; 36:449.</a></li><li><a class="nounderline abstract_t">Roy S, Kabir M, Mondal D, et al. Real-time-PCR assay for diagnosis of Entamoeba histolytica infection. J Clin Microbiol 2005; 43:2168.</a></li><li><a class="nounderline abstract_t">Qvarnstrom Y, James C, Xayavong M, et al. Comparison of real-time PCR protocols for differential laboratory diagnosis of amebiasis. J Clin Microbiol 2005; 43:5491.</a></li><li><a class="nounderline abstract_t">Blessmann J, Buss H, Nu PA, et al. Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples. J Clin Microbiol 2002; 40:4413.</a></li><li><a class="nounderline abstract_t">Madison-Antenucci S, Relich RF, Doyle L, et al. Multicenter Evaluation of BD Max Enteric Parasite Real-Time PCR Assay for Detection of Giardia duodenalis, Cryptosporidium hominis, Cryptosporidium parvum, and Entamoeba histolytica. J Clin Microbiol 2016; 54:2681.</a></li><li><a class="nounderline abstract_t">Fotedar R, Stark D, Beebe N, et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 2007; 20:511.</a></li><li><a class="nounderline abstract_t">Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003; 16:713.</a></li><li><a class="nounderline abstract_t">Hamzah Z, Petmitr S, Mungthin M, et al. Development of multiplex real-time polymerase chain reaction for detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii in clinical specimens. Am J Trop Med Hyg 2010; 83:909.</a></li><li><a class="nounderline abstract_t">Liang SY, Hsia KT, Chan YH, et al. Evaluation of a new single-tube multiprobe real-time PCR for diagnosis of Entamoeba histolytica and Entamoeba dispar. J Parasitol 2010; 96:793.</a></li><li><a class="nounderline abstract_t">Cooper CJ, Fleming R, Boman DA, Zuckerman MJ. Varied Clinical Manifestations of Amebic Colitis. South Med J 2015; 108:676.</a></li><li><a class="nounderline abstract_t">Horiki N, Furukawa K, Kitade T, et al. Endoscopic findings and lesion distribution in amebic colitis. J Infect Chemother 2015; 21:444.</a></li><li><a class="nounderline abstract_t">Tanaka E, Tashiro Y, Kotake A, et al. Spectrum of CT findings in amebic colitis. Jpn J Radiol 2021; 39:558.</a></li><li class="breakAll">Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.</li><li><a class="nounderline abstract_t">Misra NP, Gupta RC. A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis. J Int Med Res 1977; 5:434.</a></li><li><a class="nounderline abstract_t">Singh G, Kumar S. Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study. Curr Med Res Opin 1977; 5:157.</a></li><li class="breakAll">Presutti antiprotozoal agent Tindamax clears FDA; AWP is $18 per dose. In: "The Pink Sheet" vol 66, F-D-C Reports, Inc. Chevy Chase, MD 2004. p.10.</li><li><a class="nounderline abstract_t">McAuley JB, Juranek DD. Paromomycin in the treatment of mild-to-moderate intestinal amebiasis. Clin Infect Dis 1992; 15:551.</a></li><li class="breakAll">Houpt E, Hung CC.. Entamoeba histolytica (Amebiasis). In: Hunter's Tropical Medicine and Emerging Infectious Diseases, 9th ed, Magill AJ, Ryan ET, Solomon T, Hill DR (Eds), Saunders, Philadelphia 2012. p.659.</li><li><a class="nounderline abstract_t">Singh RS, Walia AK, Kanwar JR, Kennedy JF. Amoebiasis vaccine development: A snapshot on E. histolytica with emphasis on perspectives of Gal/GalNAc lectin. Int J Biol Macromol 2016; 91:258.</a></li><li><a class="nounderline abstract_t">Stanley SL Jr. Protective immunity to amebiasis: new insights and new challenges. J Infect Dis 2001; 184:504.</a></li><li><a class="nounderline abstract_t">Lotter H, Tannich E. The current status of an amebiasis vaccine. Arch Med Res 2006; 37:292.</a></li></ol></div><div id="topicVersionRevision">Topic 5727 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Peterson KM, Singh U, Petri WA Jr. Enteric Amebiasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant R, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.614.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25250228" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Laboratory methods of identification of Entamoeba histolytica and its differentiation from look-alike Entamoeba spp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22664420" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Entamoeba moshkovskii perspectives of a new agent to be considered in the diagnosis of amebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22932710" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Entamoeba bangladeshi nov. sp., Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2324531" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence and clinical importance of Entamoeba histolytica in two high-risk groups: travelers returning from the tropics and male homosexuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19580413" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A possible cluster of sexually transmitted Entamoeba histolytica: genetic analysis of a highly virulent strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103593" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infection by human immunodeficiency virus-1 is not a risk factor for amebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15738369" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18301730" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24338349" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical significance of high anti-entamoeba histolytica antibody titer in asymptomatic HIV-1-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31079045" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : An underestimated sexually transmitted infection: amoebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17991346" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Amebic colitis: new insights into pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540361" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Reassessment of the epidemiology of amebiasis: state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660071" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Amoebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30631758" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Entamoeba Histolytica: Updates in Clinical Manifestation, Pathogenesis, and Vaccine Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34046476" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fulminant amebic colitis in a patient with concomitant cytomegalovirus infection after systemic steroid therapy: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467600" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fulminant Amebic Colitis after Corticosteroid Therapy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20429861" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Insights into Entamoeba histolytica virulence modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20303955" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The immunopathogenesis of Entamoeba histolytica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12700377" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Amebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12195383" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Innate and acquired resistance to amebiasis in bangladeshi children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428733" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Entamoeba histolytica infection in children and protection from subsequent amebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207103" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recent discoveries in the pathogenesis and immune response toward Entamoeba histolytica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30046644" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20617021" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Human amebiasis: breaking the paradigm?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34450059" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : South American Entamoeba dispar strains produce amoebic liver abscesses with different pathogenicities and evolutionary kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24851190" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Entamoeba dispar: A Rare Case of Enteritis in a Patient Living in a Nonendemic Area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21396144" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Entamoeba species associated with chronic diarrhoea in Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723640" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Entamoeba moshkovskii is associated with diarrhea in infants and causes diarrhea and colitis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26004649" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Intestinal amebae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282306" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Amebic colitis in asymptomatic subjects with positive fecal occult blood test results: clinical features different from symptomatic cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37511519" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Amoebiasis: Advances in Diagnosis, Treatment, Immunology Features and the Interaction with the Intestinal Ecosystem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31299848" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Massive Lower Gastrointestinal Bleeding Due to Fulminant Necrotizing Amebic Colitis: A Diagnostic and Therapeutic Challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30624763" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antiamoebic drugs for treating amoebic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30372434" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical and microscopic predictors of Entamoeba histolytica intestinal infection in travelers and migrants diagnosed with Entamoeba histolytica/dispar infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19774426" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evolution of surgical treatment of amebiasis-associated colon perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23265426" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Amoebic toxic colitis: analysis of factors related to mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24377154" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Colonic perforation with peritonitis in amoebiasis: a tropical disease with high mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978622" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Colonic ameboma: its appearance on CT: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610001" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ileocecal masses in patients with amebic liver abscess: etiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16780468" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cutaneous amebiasis in a child and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30706890" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acute amoebic appendicitis: An unusual presentation of a usual infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30255429" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Update on laboratory diagnosis of amoebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16333901" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Microscopic overdiagnosis of intestinal amoebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1340315" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Further diagnostic use of an invasive-specific monoclonal antibody against Entamoeba histolytica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27152855" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Species-Specific Immunodetection of an Entamoeba histolytica Cyst Wall Protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8369019" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Diagnosis of pathogenic Entamoeba histolytica infection using a stool ELISA based on monoclonal antibodies to the galactose-specific adhesin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380331" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnosis of amebiasis in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466756" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of Entamoeba histolytica infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872237" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Real-time-PCR assay for diagnosis of Entamoeba histolytica infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16272475" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparison of real-time PCR protocols for differential laboratory diagnosis of amebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12454128" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27535690" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Multicenter Evaluation of BD Max Enteric Parasite Real-Time PCR Assay for Detection of Giardia duodenalis, Cryptosporidium hominis, Cryptosporidium parvum, and Entamoeba histolytica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17630338" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Laboratory diagnostic techniques for Entamoeba species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557296" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Laboratory diagnosis of amebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20889890" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Development of multiplex real-time polymerase chain reaction for detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii in clinical specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20496961" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Evaluation of a new single-tube multiprobe real-time PCR for diagnosis of Entamoeba histolytica and Entamoeba dispar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26539949" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Varied Clinical Manifestations of Amebic Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25787830" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Endoscopic findings and lesion distribution in amebic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33462730" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Spectrum of CT findings in amebic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33462730" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Spectrum of CT findings in amebic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/590600" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A comparison of a short course of single daily dosage therapy of tinidazole with metronidazole in intestinal amoebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/340132" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/340132" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Short course of single daily dosage treatment with tinidazole and metronidazole in intestinal amoebiasis: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1520807" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Paromomycin in the treatment of mild-to-moderate intestinal amebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1520807" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Paromomycin in the treatment of mild-to-moderate intestinal amebiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27181579" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Amoebiasis vaccine development: A snapshot on E. histolytica with emphasis on perspectives of Gal/GalNAc lectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11471109" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Protective immunity to amebiasis: new insights and new challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380335" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The current status of an amebiasis vaccine.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
